Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

8.4K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
8.4K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

3.1K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
3.1K
Insulin Secretory Vesicles01:05

Insulin Secretory Vesicles

7.4K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
7.4K
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

1.3K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.3K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Cell Specific Gene Expression01:58

Cell Specific Gene Expression

16.9K
Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
16.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevention of fatty acid-induced maladaptation in secretin tumor cell-1 enteroendocrine cells by allicin, a transient receptor potential ankyrin 1 agonist.

The Journal of pharmacology and experimental therapeutics·2025
Same author

An impact of type 2 diabetes mellitus on NKT-like cell population in humans: a new insight into impaired immune response in hyperglycemia.

Frontiers in endocrinology·2025
Same author

Editorial: Progress in diagnosis and treatment of hypothalamic & pituitary disorders.

Frontiers in endocrinology·2025
Same author

The Prevalence of Reduced Bone Mineral Density and the Impact of Specific Auxological Factors and Hormones on Bone Mass in Children with Endocrine Disorders.

Journal of clinical medicine·2025
Same author

Management strategies for optimal linear growth in Noonan syndrome (NS) children: minireview and case series of three patients with NS due to PTPN11 mutation and confirmed growth hormone deficiency.

Endokrynologia Polska·2025
Same author

Central Hypothyroidism with Low TSH Compared to Normal TSH Is Associated with More Advanced Pituitary Disease and Less Favorable Metabolic Profile.

Metabolites·2025

Related Experiment Video

Updated: Mar 30, 2026

Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate
05:58

Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate

Published on: June 25, 2019

8.1K

Copeptin under glucagon stimulation.

Krzysztof C Lewandowski1, Andrzej Lewiński1, Elżbieta Skowrońska-Jóźwiak1

  • 1Department of Endocrinology and Metabolic Diseases, Medical University of Lodz, Lodz, Poland.

Endocrine
|November 19, 2015
PubMed
Summary
This summary is machine-generated.

Glucagon stimulation test (GST) reveals arginine vasopressin (AVP) involvement in pituitary hormone release. Copeptin, a marker for AVP, increased with glucagon, particularly correlating with ACTH release and influenced by BMI.

Keywords:
ACTHCopeptinCortisolGHGlucagon stimulation testHypopituitarism

More Related Videos

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.8K
Author Spotlight: Investigating Islet Abnormalities and Function with a Pseudoislet Protocol
08:04

Author Spotlight: Investigating Islet Abnormalities and Function with a Pseudoislet Protocol

Published on: November 3, 2023

2.6K

Related Experiment Videos

Last Updated: Mar 30, 2026

Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate
05:58

Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate

Published on: June 25, 2019

8.1K
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.8K
Author Spotlight: Investigating Islet Abnormalities and Function with a Pseudoislet Protocol
08:04

Author Spotlight: Investigating Islet Abnormalities and Function with a Pseudoislet Protocol

Published on: November 3, 2023

2.6K

Area of Science:

  • Endocrinology
  • Neuroendocrinology
  • Pituitary Physiology

Background:

  • Glucagon stimulation test (GST) assesses pituitary function, measuring growth hormone (GH) and adrenocorticotropic hormone (ACTH) secretion.
  • The precise mechanism of glucagon's action on pituitary hormone release remains incompletely understood.
  • Arginine vasopressin (AVP) is implicated in the release of both GH and ACTH, suggesting a potential role in GST.

Purpose of the Study:

  • To investigate the role of AVP in glucagon-stimulated pituitary hormone secretion using copeptin as a surrogate marker.
  • To explore the relationship between copeptin, ACTH, GH, and cortisol levels during GST in different subject groups.
  • To assess the influence of Body Mass Index (BMI) on copeptin and hormone responses during GST.

Main Methods:

  • Measured copeptin, ACTH, cortisol, and GH levels at multiple time points during GST in 79 subjects.
  • Included healthy controls, patients with pituitary disease and adequate responses, and patients with hypopituitarism.
  • Analyzed time-dependent changes, correlations between hormones, and BMI-dependent effects on secretion.

Main Results:

  • Copeptin levels significantly increased post-glucagon stimulation in controls and patients with intact pituitary function, but not in hypopituitarism.
  • Copeptin release demonstrated a time-dependent increase and correlated strongly with ACTH increments.
  • Both copeptin and GH secretion were attenuated in individuals with higher BMI compared to those with lower BMI.

Conclusions:

  • AVP, indicated by copeptin release, is significantly involved in the pituitary response to glucagon stimulation.
  • The strong correlation between copeptin and ACTH suggests AVP/copeptin release is linked to the activation of the adrenal axis.
  • BMI-dependent modulation of copeptin and GH secretion highlights its influence on pituitary hormone dynamics during GST.